The reason for the indemnification (happened here in Germany as well) is obvious: Without "enough" (a topic for endless discussions) research and trials, the ph

The reason for the indemnification (happened here in Germany as well) is obvious: Without "enough" (a topic for endless discussions) research and trials, the pharma firms don't want to face potentially bankrupting class action law suits in case there is a minor defect with their vaccine - which they could have found if they have had more time to test it. As a business, I would do one of two things: (1) demand indemnification, or (2) raise the price high enough to cover potential damage awards; as the government doesn't want to pay (2), they go for (1).